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Introduction: Otitis media (OM) starts within weeks of
birth in almost all Indigenous infants living in remote areas
of the Northern Territory (NT). OM and associated hearing
loss persist from infancy throughout childhood and often
into adulthood. Educational and social opportunities are
greatly compromised. Pneumococcus and non-typeable
Haemophilus influenzae (NTHi) are major OM pathogens
that densely colonise the nasopharynx and infect the
middle ear from very early in life. Our hypothesis is that
compared to current single vaccine schedules, a
combination of vaccines starting at 1 month of age, may
provide earlier, broadened protection.
Methods and analyses: This randomised outcome
assessor, blinded controlled trial will recruit 425 infants
between 28 and 38 days of age and randomly allocate
them (1:1:1) to one of three pneumococcal conjugate
vaccine (PCV) schedules: Synflorix at 2, 4, 6 months of
age, Prevenar13 at 2, 4 and 6 months of age, or an
investigational schedule of Synflorix at 1, 2 and 4 months
plus Prevenar13 at 6 months of age. The blinded primary
outcomes at 7 months of age are immunogenicity of
specific vaccine antigens (geometric mean concentration
(GMC) and proportion of participants with above threshold
GMC of 0.35 µg/L). Secondary outcomes at all timepoints
are additional immunogenicity measures and proportion of
participants with nasopharyngeal carriage of vaccine-type
pneumococci and NTHi, and any OM, including any
tympanic membrane perforation. Parental interviews will
provide data on common risk factors for OM.
Ethics and dissemination: Ethical approval has been
obtained from NT Department of Health and Menzies
HREC (EC00153), Central Australian HREC (EC00155) and
West Australian Aboriginal Health Ethics Committee
(WAAHEC- 377-12/2011). Final trial results, data analyses,
interpretation and conclusions will be presented in
appropriate written and oral formats to parents and
guardians, participating communities, local, national and
international conferences, and published in peer-reviewed
open access journals.




In the Northern Territory of Australia, otitis
media (OM) is a major public health crisis.
By 3 months of age all infants have had a
diagnosis of OM, and the episode persists for
months.1 2 Our studies have identiﬁed com-
munities where as many as 60% of children
under 2.5 years of age have tympanic
Strengths and limitations of this study
▪ This study addresses an important health and
social issue for Australian Indigenous children who
live in the only western country named by the WHO
as being in the highest category (>6%) of chronic
suppurative otitis media (CSOM) prevalence.
▪ This study is a randomised controlled trial of
two licensed pneumococcal conjugate vaccines
(PCVs) and a novel early combination schedule
of these vaccines. Funding is independent of
vaccine manufacturers.
▪ Primary outcomes are accepted global immuno-
genicity criteria for licensing and varying PCV
schedules. Secondary nasopharyngeal carriage
outcomes are measured according to WHO recom-
mendations. Secondary clinical outcomes are pre-
published standardised assessments of middle ear
status.
▪ Limitations of the study include small sample size
for secondary outcomes and slow recruitment.
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membrane perforations (TMP). Less than 20% children
have normal aerated middle ears.3 The conductive
hearing loss associated with persistent middle ear effu-
sion (around 25 dB) or TMP (35–60 dB) has detrimen-
tal effects on auditory processing, speech and language
development, behavioural and communication skills,
and educational achievement. In randomised controlled
trials, compared to placebo, long-term amoxicillin has
been shown to halve the risk of TMP4 and long-term
topical antibiotics will resolve the ear discharge (but not
the perforation) in only 30% children.5 Health services
struggle to deal with the diagnosis of acute OM (AOM),
and with the management of perforation or persistent
hearing loss. Surgical options are rarely available.
Strategies to prevent early ear disease or reduce the inci-
dence, duration and severity of disease are urgently
needed.
Onset of ﬁrst OM is preceded by acquisition of bacter-
ial pathogens that colonise the nasopharynx soon after
birth.1 The primary pathogens recovered from ear dis-
charge of Aboriginal children with AOM with perfor-
ation (AOMwiP) in the ﬁrst 18 months of life are
pneumococcus (Spn), and non-typeable Haemophilus
inﬂuenzae (NTHi). Pre-PCVs (pneumococcal conjugate
vaccines) Pneumococcus was recovered from 38% middle
ear discharge samples and NTHi from 55%.6
Our research question is to determine the potential for
the two licensed PVCs PHiD-CV10 and PCV13 to be used
early and in combination to broaden protection from the
OM pathogens. The combination schedule chosen
(PHiD-CV10 at 1, 2 and 4 months plus PCV13 at
6 months) was based on (1) data showing improved HiD
immunogenicity following a third dose of PHiD-CV10
compared to two doses (data provided by GSK), (2) the
opportunity to start vaccination earlier, at 1 month rather
than 2 months of age, (3) the Northern Territory’s rela-
tively low prevalence of invasive pneumococcal disease
caused by PCV13-only serotypes 3, 6A and 19A (com-
pared to other serotypes) and (4) data showing reason-
able immune response to a single dose of PCV.7
If superior, the COMBO vaccine schedule is likely to
be recommended for Indigenous infants living in high-
risk populations.
Explanation for choice of comparators
Three PCVs were licensed or soon to be licensed in
Australia at the time of writing this proposal in 2009. PCV7
had been effective in eradicating almost all OM episodes
caused by the seven vaccine serotypes. However, this eradi-
cation had not been translated to a clinical beneﬁt6 due to
replacement disease by non-PCV7 serotypes8 and a signiﬁ-
cant role of NTHi as a primary pathogen in TMP
(Pneumococcus was recovered from around 31% middle ear
discharge samples from PCV7-vaccinated children less than
18 months of age and NTHi from 58%).6 We also believe
persistent high rates of pneumonia in the Northern
Territory9 are not necessarily related to low efﬁcacy of
PCV7, but to serotype replacement and additional
pathogens including NTHi, as shown in Papua New
Guinea.10 Extended coverage vaccines are urgently
needed. One strategy with potential to extend serotype
coverage has been addressed by another study of ours
(NHMRC 490320 ‘PneuMum’),11 which has evaluated
maternal immunisation with Pneumovax (23-valent
pneumococcal polysaccharide vaccine, 23PPV) to provide
early and expanded serotype protection in Indigenous
infants. In 2006, results of an RCT of 11-valent PCV
(pneumococcal H. inﬂuenzae protein D conjugate vaccine,
11Pn-PD) showed efﬁcacy for vaccine-type pneumococcal
AOM and NTHi-AOM.12 The 10-valent vaccine,
PHiD-CV10, was licensed on the basis of immunogenicity
of the pneumococcal antigens and in 2009 was under con-
sideration by Therapeutic Goods Administration for recom-
mendation in Australia. In October 2009, the Northern
Territory was the only Australian jurisdiction to change
recommendations for PCV from PCV7 at 2, 4 and
6 months (followed by PPV23 at 18 months for Indigenous
children), to PHiD-CV10 at 2, 4, 6 and 18 months (for all
children). In 2011, the 13-valent CRM197-conjugated
vaccine, Prevenar13, was approved in Australia as a 2, 4 and
6 month schedule (followed by PCV13 at 18 months for
Indigenous children). In October 2011, Prevenar13
replaced PHiD-CV10 in the Northern Territory.
Objectives
Speciﬁc objectives or hypotheses.
Overall objective
To determine if the COMBO vaccination schedule is
superior to the other two vaccination schedules with
regard to overall protection from OM pathogens.
Primary hypotheses:
▸ The COMBO group will have greater immunogenicity
for HiD* compared to the PCV13 group at 7 months;
▸ The COMBO group will have greater immunogenicity
to pneumococcal serotype 19A** compared to the
PHiD-CV10 group at 7 months;
▸ The COMBO group will have greater immunogenicity
to pneumococcal serotype 3** compared to the
PHiD-CV10 group at 7 months;
▸ The COMBO group will have greater immunogenicity
to pneumococcal serotype 6A** compared to the
PHiD-CV10 group at 7 months.
Key secondary hypotheses
▸ The COMBO group will have less carriage of NTHi*
compared to the PCV13 group at 7 months;
▸ The COMBO group will have less carriage of pneumo-
coccal serotype 19A** compared to the PHiD-CV10
group at 7 months;
▸ The COMBO group will have less carriage of pneumo-
coccal serotype 3** compared to the PHiD-CV10
group at 7 months;
▸ The COMBO group will have less carriage of pneumo-
coccal serotype 6A** compared to the PHiD-CV10
group at 7 months;
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▸ The COMBO group will have less OM compared to
the PCV13 group at 7 months;
▸ The COMBO group will have less OM compared to
the PHiD-CV10 group at 7 months.
*HiD is not in PCV13, but is in PHiD-CV10.
**Serotypes in PCV13 but not in PHiD-CV10 are: 3,
6A and 19A.
METHODS
Participants, interventions and outcomes
Trial design
The PREVIX_COMBO trial is an open label, allocation
concealed, primary outcome assessor blinded, parallel
group and randomised controlled trial with three
groups (1:1:1), to determine the superiority of combin-
ation schedule over single vaccines.
Study setting
The trial will take place in remote Aboriginal and Torres
Strait Islander communities (see ﬁgure 1). Traditional
Owners (elders) have provided signed agreement for
their community to participate in this research.
Eligibility criteria
Participants: Inclusion criteria—Aboriginal or Torres
Strait Islander male and female infants living in a
participating remote community (whose Traditional
Owners have provided signed Expressions of Interest
and conﬁrmation of participation in PREV-IX_COMBO
trial) in the Northern Territory or Western Australia,
28–38 days of age, healthy and eligible for National
Immunisation Programme routine vaccines.
Exclusion criteria: Prior adverse reaction to PCVs
according to the Australian Immunisation Handbook;
gestational age <32 weeks. Not the eldest of the multiple
births. Parents (usually the mother) are asked whether
they expect to be resident in that community until their
baby is 7 months of age. Those planning to move to a
non-participating community are not eligible to be in
the study.
Interventions and dosing schedules
Infants are randomly allocated in a 1:1:1 ratio to (1)
Synﬂorix (PHiD-CV10) at 2, 4 and 6 months of age,
(2) Prevenar13 (PCV13) at 2, 4 and 6 months of age or
(3) the combination schedule of PHiD-CV10 at 1, 2 and
4 months, and PCV13 at 6 months of age. Infants allo-
cated the combination schedule received a single dose
of PHiD-CV10 at the time of randomisation (table 1).
Study vaccines are administered into the left anteriolat-
eral thigh. Immunisations are performed by nurses who
had completed the About Giving Vaccines course.
Criteria for discontinuing
Infants may be withdrawn from the study by their parent
(s), guardian, the local healthcare provider or study staff.
Strategies to improve adherence
Parents are advised of their baby’s scheduled visit dates.
Where the parent provides a contact phone number,
calls are made in advance to advise of a scheduled study
visit. A dedicated study vehicle is available to transport
parents and infants from their homes to the local clinic
to receive vaccinations and healthcare by research staff.
Parents receive a small gift following each of the two
longer study visits which include a blood draw.
Relevant concomitant care
Research nurses also provide all vaccinations according to
the current National Immunisation Programme for the
Indigenous population. Infants receive treatment or refer-
ral for all concomitant conditions, particularly ear, skin,
respiratory and growth problems, according to local guide-
lines.13 No concomitant medications were prohibited.
Outcomes
Primary, secondary and other outcomes.
Immunogenicity
Serotype-speciﬁc IgG are measured using a modiﬁed
third-generation ELISA based on WHO recommenda-
tions.14 Sample dilutions are analysed in duplicate and
three controls (low, medium and high) are included on
each plate. Serotype-speciﬁc IgG is measured onto 13
Figure 1 PREV-IX_COMBO study sites in the Northern
Territory and Western Australia.
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vaccine serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 15B, 18C,
19F and 23F. IgG antibodies to the protein D of H. inﬂu-
enzae is measured by a classic ELISA, with non-lipidated
protein D as coating material and expressed in ELISA
units (EL.U/mL). Data are analysed using GraphPad
Prism V.5 (GraphPad Software Inc, USA). Pneumococcal
serotype-speciﬁc antibody concentrations and HiD anti-
body concentration are log10 transformed, and the geo-
metric mean concentration (GMC) and 95% CIs are
determined. Serotype-speciﬁc and HiD IgG GMC com-
parisons are made using unpaired t tests of the logged
data.15
Nasopharyngeal carriage and ear discharge microbiology
NP swabs are collected, transported and stored as previ-
ously described,5 and in accordance with WHO recom-
mendations for pneumococcal NP carriage studies.16
Swab quality is also recorded as good (swab inserted to
the NP and held for 5 s), fair (swab inserted partially
and brieﬂy), poor (swab of outer nares only) or very
poor (outer nares and no discharge visible). Any swab
with visible secretions is coded as ‘good’. Swabs of ED
are collected after cleaning the external canal and col-
lecting discharge from as close as possible to the TMP.5
NP and ED swabs are cultured on selective and non-
selective media, and semiquantitative colony counts
recorded as previously described.5 Bacterial and viral
DNA are extracted for detection by pathogen-speciﬁc
quantitative PCR. For ED swabs with swarming species
that preclude selection of single NTHi colonies, a milli-
pore ﬁltration step is used.5 At least two presumptive
pneumococcal colonies and two presumptive NTHi col-
onies are selected from each specimen for conﬁrmation.
Colonies of minority colony morphology are chosen, if
present. Pneumococci are identiﬁed by colony morpho-
logy, optochin sensitivity and positive reaction with
typing sera (Statens Serum Institut, Denmark); serotype
is determined by Quellung reaction. NTHi are identiﬁed
by colony morphology, dependence on X and V growth
factors, and lack of reaction with capsular antisera using
the Phadebact Haemophilus coagglutination test. PCR
discrimination of Haemophilus haemolyticus is not uni-
formly undertaken after conﬁrmation that less than
0.2% presumptive NTHi isolated from NP swabs in this
population are misidentiﬁed.17 Antimicrobial susceptibil-
ity is determined by the calibrated dichotomous suscepti-
bility (CDS) disc diffusion method.18 19 Minimum
inhibitory concentrations (MICs) are determined for
macrolide and β-lactam antibiotic resistance in
Streptococcus pneumoniae isolates and azithromycin resist-
ance in NTHi isolates using Etest strips (AB bioMérieux,
Sweden). β-Lactamase production by NTHi is deter-
mined using nitrocephin (Oxoid, Australia). Resistance
is deﬁned using European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints (http://www.
eucast.org). Penicillin non-susceptibility of Spn is deﬁned
as MIC >0.06 mg/L and azithromycin resistance as MIC
>0.5 mg/L. Azithromycin resistance in NTHi is deﬁned as
MIC >4 mg/L; intermediate resistance as MIC >0.12 and
≤4 mg/L, and susceptibility as MIC ≤0.12 mg/L.
Otitis media
Ear examinations and general health assessments: All
clinical assessments are made by ear health research
nurses with extensive training in the diagnosis and man-
agement of OM in this population. Otoscopic ﬁndings
Table 1 Schedule of enrolment, interventions, and assessments
Study period
Enrolment Allocation Postallocation
Study visit number 1 1 2 3 4 5
Age (months) 1 1 2 4 6 7
Allocation x
Eligibility screen x x
Informed consent x x
Interventions
Group 1 PHiD-CV10 x x x







Fixed, eg, sex, birth weight, gestational age, maternal education x
Not fixed, eg, household occupancy, smoke exposure, breastfeeding x x
Ear assessment
Tympanometry x x x x x
Otoscopy x x x
Nasopharyngeal swab x x x x
Blood draw (heel prick or venepuncture) x* x* x
General health (skin, chest, nose, temp, weight, length) x x x x x
*Blood draw occurs at either 2 or 4 months of age (decided by a random process).
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are recorded on a standardised form. Assessments are
made using a tympanometer (Grason Stadler GSI 38), a
LumiView (Welch Allyn), and a video-otoscope (Welch
Allyn macroview or MedRx video-otoscopes).
Deﬁnitions of OM: We categorise middle ear states as
follows: (1) normal; (2) OM with effusion (OME); (3)
acute OM without perforation (AOMwoP); (4) AOM with
perforation (AOMwiP); (5) dry perforation and (6)
chronic suppurative OM (CSOM). The ﬁnal middle ear
diagnosis reﬂects the child’s most severely affected ear
(highest category). Criteria for diagnosis are based on
recommendations for clinical practice in this population20:
(1) OME—intact and non-bulging tympanic membrane
(TM) and type B tympanogram; (2) AOMwoP—any
bulging of the TM and type B tympanogram; (3) AOMwiP
—middle ear discharge observed and TM perforation
recently healed or present for less than 6 weeks or cover-
ing less than 2% of the pars tensa of the TM; (4) dry per-
foration—TM perforation without any discharge observed
and (5) CSOM—middle ear discharge observed and per-
foration present for longer than 6 weeks and covering at
least 2% of the pars tensa of the TM. Combination cat-
egories of any suppurative OM (any AOM, AOMwiP or
CSOM) and any TMP (any AOMwiP, dry perforation or
CSOM) are included. Where duration of discharge is not
known, size of perforation is used to distinguish AOMwiP
and CSOM. Where otosocopy is not successful the infant’s
tympanometry result is used and the infant’s status is
deﬁned as OME if either ear had a type B tympanogram.
We ask the mother if she thought her baby had ear pain
that day or during the previous evening. These a priori
diagnostic criteria have been applied in all our surveil-
lance and clinical trials conducted in this population since
2001.3
Other outcomes
General health measures: Common conditions of child-
hood are recorded at the time of ear assessment by
direct observation; axillary temperature, the infant’s skin
(head, arms, legs and trunk) is examined for the pres-
ence of scabies, tinea, skin sores or other skin condition;
presence of nasal discharge (visible at a distance of 1 m)
and any cough (spontaneous or cough on request,
either wet or dry). We categorise ‘not sure’ as absent.
Antibiotics and other treatments or referrals are pro-
vided to participants according to local guidelines.
Risk factor questionnaires: The parent or guardian
(usually the mother) is asked a standardised set of ques-
tions about common risk factors for OM, including the
number of children she has, the number of people and
children (less than 5 years of age) living in the infant’s
house, whether the mother or infant’s siblings ever had
TMP (‘runny ears’), the mother’s highest level of educa-
tion, whether the mother smokes, smoked during preg-
nancy or if she or other household members smoke
inside the house, and whether the infant was exposed to
campﬁre smoke during the previous week, had ever
used a paciﬁer, or was ever breastfed or bottle fed.
Sample size
Immunogenicity: Target enrolment is 425 participants to
provide 339 evaluable infants (113 per group) at
7 months (we assume 20% withdrawal and/or loss to
follow-up over the total study period).
Immunogenicity: If 20% of mothers refuse blood col-
lection, bloods from 270 infants at 7 months will be
available, 90 from each group. This will provide 99%
power to detect an increase in the proportion of infants
with immunogenicity above threshold for 3, 6A or 19A
from 20%, 37% or 57%, respectively (data from non-
vaccinated controls21) in the PHiD-CV10 group to 87%
for 6A and >90% for 19A in the COMBO group (data
from single toddler dose7), and for anti-HiD, there will
be 90% power to detect a 21% increase from 67% in the
PCV13 group to 88% in the COMBO group (data from
adults receiving two doses HiD22).
Carriage: We will have over 90% power to detect
reductions in NTHi and 19A carriage at 7 months of
age, from 80% to 50% (for NTHi) and 20% to 5%
(for 19A), respectively, between the COMBO group and
the PCV13 group (for NTHi), and the COMBO group
and PHiD-CV10 group (for 19A).
OM: We will have 55% power to detect a doubling in the
proportion of children free from OM at 7 months in the
COMBO group compared to another group (20% vs 10%).
Four hundred and twenty-ﬁve is likely to be plenty for
the primary outcomes and insufﬁcient for the secondary
outcomes. The PREV-IX_BOOST study (see online sup-
plementary appendix for a brief description) depends on
this trial achieving 7-month follow-up on ∼300 infants.
Progress to date: Randomisations started in September
2011 and will be completed in late 2016.
Recruitment and participant selection
Each local health service provider is regularly briefed
about the study and the midwives asked to notify us of
pregnant women who may have an interest in participat-
ing. The research staff provide potential participants
with verbal, written and pictorial study information with
assistance in local language from community members.
Written informed consent or assent (from mothers
younger than 16 years of age) is obtained when the baby




Sequence generation: The allocation sequence is generated
by the NHMRC Clinical Trial Centre (NHMRC_CTC) ran-
domisation service. Minimisation is used to guarantee
balance by community.
Allocation concealment mechanism: An independent
centralised telephone service is employed to determine
allocation at the time of the call from the study research
nurse.
Implementation: The research nurse calls the auto-
mated NHMRC_CTC 24/7 randomisation service with
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information regarding the eligibility of the participant,
and community. The allocation to one of the three study
interventions is received immediately and conﬁrmed.
The allocation is also immediately provided to the study
coordinator by conﬁdential fax.
Blinding (masking): The primary outcome (immuno-
genicity) assessors are blinded to the vaccine group allo-
cation. Samples are labelled with a sample random
number before being transported to Melbourne for
testing. Only the Menzies database manager has the code
for linking the participant to the immunogenicity data.
The secondary outcomes (nasopharyngeal carriage with
OM pathogens and OM) are not blinded. Unblinding a
participant’s allocated intervention during the trial will
be permissible only if requested in writing by the iDSMB
following a unanimous decision by the iDSMB to do so
and in accordance with the Terms of Reference.
Data collection, management and analysis
Data collection methods
Data quality: Standardised assessment and data collection
forms are used. For the primary outcomes (immunogeni-
city), the collection method (heel prick or venepuncture)
and volume of whole blood is recorded. For the nasopha-
ryngeal swabs, the WHO recommendations are followed
and swab quality is recorded according to a standardised
category (good, fair, poor). For OM, a standardised form
is used to record detailed clinical features of the diagnosis.
Features include presence of wax, pus or foreign bodies in
the canal, TM colour and translucency, position and
degree of bulging, integrity and perforation size, amount
of discharge. The ﬁnal diagnosis for each ear is deter-
mined by the research nurse for purposes of disease man-
agement. Tympanometry is performed and results
printed. Diagnostic algorithms are checked using the clin-
ical feature scores and tympanogram. A video recording of
the TM is used to assist the diagnostic decisions.
Retention: Participant retention till 7 months of age is
promoted through the eligibility criteria (intention of
the family and infant to remain in the community) and
encouragement at each interaction with the study staff.
Data management
Data collected during each study visit are recorded on
standardised forms in participant workbooks. Paper
forms are returned to the Menzies ofﬁce and data
entered electronically by the research nurse into a
MySQL database with Microsoft Access front-end, within
1 week of data collection. A protocol for changing data
on paper according to Good Clinical Practice is used
and all changes made electronically are tracked on the
database. Microbiology data are entered directly onto
the same MySQL database by the laboratory scientist. All
data are checked using a series of logical checks and
10% of all electronic data are cross-checked with paper
forms. An overall error rate of 1:200 precipitates a 100%
check of targeted data ﬁelds and a further 10% check of
all data. Immunology results are sent in an Excel
spreadsheet via email to the senior database manager at
Menzies to be linked with the main database at the time
of unblinding.
Statistical methods
The description below describes the main analyses of
the trial that will be reported.
Analyses will be by intention to treat (ITT) and
according to protocol (ATP). All available outcome data
that are collected at each timepoint (ITT) (table 1), and
data collected within the study visit window for each
timepoint (ATP) will be used. There will be no imput-
ation of outcomes where data are missing (ﬁgure 2). It
is expected that compliance will be high and will not
vary according to treatment group.
The distribution of IgG for each of the pneumococcal
serotypes 3, 6A and 19A as well as for HiD will be pre-
sented for the three groups at the three timepoints
using (1) boxplots and (2) the proportion of infants
above a threshold (pneumococcal serotype-speciﬁc IgG
>0.35 μg/mL and HiD IgG >100 EL.U/mL).
Carriage data, for each of the pneumococcal serotypes
3, 6A and 19A as well as for NTHi, will be presented for
the three groups (as proportions) at the four timepoints.
OM data will be presented for the three groups (as
proportions) at the four timepoints.
Two-sided p values (unadjusted for multiplicity) from
Mann-Whitney tests on IgG data and Fisher’s exact tests
comparing proportions with carriage and proportions with
OM will be reported for (1) COMBO group versus
PHiD-CV10 group at infant age 7 months and (2) COMBO
group versus PCV13 group at infant age 7 months.
Monitoring
Data monitoring
Data monitoring committee: An independent Data
Safety and Monitoring Board (iDSMB) and Terms of
Reference were established before the ﬁrst randomisa-
tion. The iDSMB met three monthly via teleconferences
in the ﬁrst year, followed by six monthly meetings.
Participant recruitment and retention, protocol devia-
tions and violations, reactogenicity, adverse events and
serious adverse events are regularly reviewed. Aggregate
clinical and NP carriage outcomes, and adequacy of
blood collection for immunogenicity outcomes are
reported. A closed session is scheduled for the end of
each iDSMB meeting. Further details can be found in
the PREVIX_COMBO Trial Master File held on the
Menzies secure server.
Interim analyses and stopping: There are no interim
analyses planned. Stopping guidelines are based on
safety alone and will be a decision made by the iDSMB
according to the Terms of Reference. The iDSMB will
hold an extraordinary meeting to discuss modiﬁcation,
suspension or termination of the trial on the grounds of
safety. Interim independent analyses may be requested
to establish whether the trial result has been attained or
will not be able to be attained. Should it be felt
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necessary, the iDSMB may request interim independent
analyses.
Harms: Standardised data collection forms are used to
extract data from the medical records on adverse events
(anticipated reactogenicity and unanticipated events),
including hospitalisation. Adverse reactions are directly
observed during postvaccination period of 15 min. The
iDSMB is informed about population trends in hospita-
lised cases of the disease potentially related to interven-
tions or the probable-related adverse events. The NT
Department of Health, Disease Control provides monthly
data on cases of Invasive Pneumococcal Disease (total
cases and cases of serotype 3, 6A and 19A by ethnicity,
age and location). Notiﬁcations of hospitalised cases of
bronchiolitis at Royal Darwin Hospital are also provided,
as bronchiolitis is the most common cause of hospitalisa-
tion in the age group of this vaccine trial. An independ-
ent safety monitor assesses relatedness of adverse events
to study intervention.
Auditing: An independent trial monitoring consultant
(Clinical Network Services) has been appointed to
monitor the PREVIX_COMBO trial processes and
documentation at key milestones including after the ﬁrst
ﬁve randomisations to the COMBO group, after 50% of
all randomisations and after 75% of all randomisations.
The processes reviewed include study progress, identiﬁ-
cation of unreported SAEs, review of informed consent
for all participants, performing source document veriﬁ-
cation of completed Case Report Forms (according to
visit schedule, eg, 100% visit 1 COMBO group partici-
pants, 10% other visits), review investigational product
accountability and handling, review biological sample
handling and storage, review investigator site ﬁle main-
tenance, ensure applicability to HREC and regulatory
approvals/reporting. Document and seek corrective
action for all discrepancies and ﬁndings. The consultant
will provide the sponsor (Menzies School of Health
Research) with the report within 15 working days.
ETHICS AND DISSEMINATION
Research ethics approval
The PREVIX_COMBO trial has ethical approval from all
relevant human research ethics committees in the
Figure 2 Participant flow chart.
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Northern Territory and in Western Australia, namely the
Human Research Ethics Committee of the Northern
Territory Department of Health & Families and the
Menzies School of Health Research (HREC—EC00153),
the Central Australian Human Research Ethics Committee
(CAHREC—EC00155), and the West Australian Aboriginal
Health Information Ethics Committee (WAAHIEC—
377-12/2011). Progress reports are provided according to
each EC reporting templates.
Protocol amendments
All protocol modiﬁcations are reported to the relevant
HREC in the Northern Territory and in Western Australia.
Trial registries are regularly updated. Investigators, the
iDSMB and other stakeholders, including participating
community health services, are advised of important
protocol amendments, such as those that may impact on
participant safety, scientiﬁc validity, scope or ethical rigour.
Substantive protocol amendments are agreed by the
PREVIX_COMBO investigator team and are approved by
HREC before implementation. Minor administrative
amendments are documented in notes to ﬁle.
Consent or assent
Who obtains consent: Only staff who have been appro-
priately trained are conducting informed consent and
assent. Community midwives ask pregnant women if
they would like to discuss enrolling their baby in a study
of baby needles for ear health. If the mother agrees, the
midwife notiﬁes the research nurses of the mothers’
contact details. Information is provided to these parents
(usually the mother) in written, verbal and pictorial
formats (see online supplementary appendix), including
verbal translation where requested. Consultation com-
mences during pregnancy to allow sufﬁcient time for
families to be broadly consulted. Signed consent is not
required until the infant is between 28 and 38 days of
age, when the eligibility criteria are conﬁrmed. The
consent process includes explanations of all elements of
consent according to Good Clinical Practice, the
Declaration of Helsinki, NHMRC requirements and
according to local requests to ensure cultural safety
(as recommended by the Indigenous Reference Group).
Ancillary studies: Additional consent is sought from
parents or guardians to use participant data and bio-
logical specimens for future research relating to OM.
Options to refuse each or all requests are provided,
including whether permission is granted to send speci-
mens to other laboratories and for the disposal of bio-
logical specimens.
Confidentiality
Personal information is collected on standardised paper
forms. Data are collected from participants’ medical
records and by face-to-face interview. Paper-based infor-
mation is stored in locked cabinets with limited access at
Menzies School of Health Research and electronic data is
stored on a secure password protected server. Participant
ID codes are used. Names are removed for analysis pur-
poses. Electronic data are reidentiﬁable if required by
regulatory authorities or by the HREC or iDSMB.
Specimens are labelled with participant ID code and will
be destroyed at the end of the study according to the par-
ticipants’ requests made during the consent process.
Access to data
The ﬁnal trial dataset will be under the custody of the
trial sponsor, the Menzies School of Health Research.
The Menzies senior data manager will have access to the
full anonymised ﬁnal dataset. Access to the ﬁnal dataset
or identiﬁable data by others will require written
requests to be approved by the HREC, iDSMB, all study
Investigators and the Director, Menzies.
Ancillary and post-trial care
All participants have access to ancillary care from their
usual health care provider (local community health
centre). Should the trial show beneﬁt or harm of the
any vaccine schedule, recommended vaccination sche-
dules may change accordingly. This will not be likely to
affect trial participants who will not be age- eligible for
primary course vaccination by the time this information
will be available.
Compensation for trial participants for trial- related
harms are provided through the trial insurance and
indemnity by the Menzies School of Health Research.
Dissemination policy
Plans: Trial results will be communicated in aggregate to
participant families and their communities via written
and oral presentations. Results will be provided for indi-
vidual communities if requested (randomisation is strati-
ﬁed by community). Trial results will be published in
peer-reviewed international journals, will be presented at
relevant national and international conferences, and will
be reported to local policy makers (Australian Technical
Advisory Group on Immunisation, Therapeutic Goods
Administration and the Pharmaceutical Beneﬁts Advisory
Committee) with the responsibility for immunisation in
Australia. Additional stakeholders, including the trial
funders (NHMRC and Financial Markets for Children)
and vaccine manufacturers, will be informed of the trial
ﬁndings. Results will be disseminated regardless of the
magnitude or direction of effect. There are no publica-
tion restrictions.
Authorship eligibility
A Publication Subcommittee will be appointed to review
and classify all proposed publications according to the
PREVIX publication guidelines. Publications will be clas-
siﬁed according to outcome reported (A, primary; B,
secondary; C, ancillary), target audience (i, international;
ii, national; iii, local) and medium (1, journal; 2, oral; 3,
poster). Authorship will be proposed by lead authors and
approved by the Publications Subcommittee according to
journal or other guidelines. If no clear journal or other
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guidelines are provided, the Publications Subcommittee
will refer to established recommendations of peer-
reviewed international journals. The role of each author
will be published. The goal is to acknowledge substantive
contributions to design, conduct, interpretation and
reporting of the trial through authorship, and to
enhance transparency and avoid disputes or misunder-
standing after trial completion. Protocol authors will be
acknowledged in subsequent publications for their role
in design. All NHMRC grant application chief investiga-
tors and associate investigators will be acknowledged as
group authors for their role in funding, in addition to
any additional individually-named authorship on the
basis of criteria and approved by the Publication
Subcommittee. All study staff who participate for at least
one full-time year or equivalent will be named as a group
author and acknowledged for their role. Where journals
do not allow such groups to be acknowledged, this publi-
cation or the PREVIX_COMBO protocol will be cited as
reference for the full authorship group.
Committees
The Child Health Division of the Menzies School of
Health Research has convened an Indigenous Reference
Group (CHD_IRG), chaired by Professor Ngiare Brown.
The IRG is comprised of Indigenous members with
expertise in science, ethics and Indigenous affairs. Role of
the CHD_IRG is to review and advise on cultural relevance
of research, from inception to implementation. Prof
Leach regularly reports to the CHD_IRG and seeks their
advice and feedback. CHD_IRG members: Chair:
N Brown. Members: Pirrawayingi (M Puruntatameri),
M Mayo, L Murakami-Gold, D Campbell, B Lee,
E Hawthorn, I Raye, L Quall (secretariat).
An independent Data Safety and Monitoring Board
(iDSMB) review participant recruitment and retention,
protocol deviations and violations, reactogenicity, adverse
events and serious adverse events. Aggregate clinical and
NP carriage outcomes, and adequacy of blood collection
for immunogenicity outcomes are reported. PREVIX
iDSMB members: Chair: D Isaacs. Members: T Nolan,
H Gunasekera, P Forder, N Woods, H D’Antoine.
An independent Study Monitor (N Woods) assesses
relatedness of adverse events to study intervention.
Data management group. The PI, Prof Leach, is respon-
sible for data quality, security and regulatory requirements.
The Menzies Data Management Group, led by Mrs Robyn
Liddle and currently, Mr Steve Buchanan, manage the
database and Ms Jemima Beissbarth manages the data dic-
tionary and data cleaning.
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